Argenica Therapeutics (ASX:AGN) reports drug inhibits a cause of Alzheimers

 Argenica Therapeutics (ASX:AGN) has announced positive initial preclinical data showing that its drug ARG-007 significantly inhibited the aggregation of human recombinant Amyloid-Beta (Abeta) in a cell-free Abeta aggregation assay model.

Abeta aggregation is thought to be one of the main causes of Alzheimer’s Disease, and the data showed a 25 µM dose of ARG-007 reduced Abeta aggregation by more than 50% compared to vehicle controls.

Argenica Therapeutics will now progress to animal studies to further confirm the efficacy of ARG-007 in Alzheimer’s Disease and will update the market as milestones are met.

Its share price is up 25% this morning.